Farmakoterapia w Psychiatrii i Neurologii

Pełna treść

2/2023 vol. 39
Artykuł przeglądowy

Potencjał terapeutyczny N,N-dimetylotryptaminy w leczeniu zaburzeń psychicznych i neurodegeneracyjnych

Jakub Schimmelpfennig 1
,
Kamila Jankowiak-Siuda 1
  1. Behavioral Neuroscience Lab, SWPS University Faculty of Psychology in Warsaw, Poland; Centrum Neuronauki Behawioralnej, Instytut Psychologii, Uniwersytet SWPS w Warszawie, Polska
Farmakoterapia w Psychiatrii i Neurologii 2023, 39 (2), 115–130
DOI: https://doi.org/10.5114/fpn.2023.131979
Data publikacji online: 2024/01/19
Plik artykułu
03ER_IPiN_FARM_2023-2D.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Andersson M, Persson M, Kjellgren A. Psychoactive substances as a last resort – a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J 2017; 14: 1-10.
  2. Barker SA. Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT. Psychopharmacology 2022; 239 (6): 1749-63.
  3. Barker SA. N,N-Dimethyltryptamine (DMT), an endogenous hallucinogen: Past, present, and future research to determine its role and function. Front Neurosci 2018; 12: 536.
  4. Batalla M. All-natural 5-MeO-DMT sigma receptor 1 agonist and its therapeutic impact in mental and neurodegenerative diseases through mitochondrial activation. Science Reviews. Biology 2023; 2 (2): 1-20.
  5. Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 2023; 48: 104-12.
  6. Callaway JC, Grob CS. Ayahuasca Preparations and Serotonin Reuptake Inhibitors: A Potential Combination for Severe Adverse Interactions. Journal of Psychoactive Drugs 1998; 30: 367-9.
  7. Cameron LP, Benson CJ, Dunlap LE et al. Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. ACS Chem Neurosci 2018; 9: 1582-90.
  8. Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull 2016; 126: 74-88.
  9. Carhart-Harris R, Nutt D. Serotonin and brain function: a tale of two receptors. J Psychopharmacol 2017; 31: 1091-120.
  10. Carhart-Harris R, Giribaldi B, Watts R et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 2021; 384: 1402-11.
  11. Dean JG, Liu T, Huff S et al. Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain. Sci Rep 2019; 9: 9333.
  12. Dos Santos RG, Hallak JEC. Effects of the Natural β-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies. Journal of Psychoactive Drugs 2017; 49: 1-10.
  13. D’Souza DC, Syed SA, Flynn LT et al. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 2022; 47: 1854-62.
  14. Eckernäs E, Timmermann C, Carhart‐Harris R et al. N,N‐dimethyltryptamine affects electroencephalography response in a concentration‐dependent manner – A pharmacokinetic/pharmacodynamic analysis. CPT Pharmacomet Syst Pharmacol 2023; 12: 474-86.
  15. Fanibunda SE, Deb S, Maniyadath B et al. Serotonin regulates mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT 2A receptor and SIRT1-PGC-1α axis. Proc Natl Acad Sci U S A 2019; 116: 11028-37.
  16. Fanibunda SE, Vaidya VA. Serotonin minting new mitochondria in cortical neurons: implications for psychopathology. Neuropsychopharmacol 2021; 46: 259-60.
  17. Fissler P, Vandersmissen A, Filippi M et al. Effects of serotonergic psychedelics on mitochondria: Transdiagnostic implications for mitochondria-related pathologies. Journal of Psychopharmacology 2023; 37 (7): 679-86.
  18. Filippi M, Krähenmann R, Fissler P. The Link Between Energy-Related Sensations and Metabolism: Implications for Treating Fatigue. Front Psychol 2022; 13: 920556.
  19. Fontanilla D, Johannessen M, Hajipour AR et al. The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator. Science 2009; 323: 934-7.
  20. Frecska E, Kovacs A. The protective role of dimethyltryptamine and its analogues against ischemia-reperfusion injury: Commentary. Neuroscience 2021; 2: 39-42.
  21. Gardner D, Riet-Correa F, Lemos D et al. Teratogenic effects of Mimosa tenuiflora in a rat model and possible role of N-methyl-and N,N-dimethyltryptamine. Journal of agricultural and food chemistry 2014; 62: 7398-401.
  22. Gattuso J J, Perkins D, Ruffell S et al. Default Mode Network Modulation by Psychedelics: A Systematic Review. Int J Neuropsychopharmacol 2023; 26 (3), 155-88.
  23. Goguadze N, Zhuravliova E, Morin D et al. Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress. Neurotox Res 2019; 35: 1-18.
  24. Good M, Joel Z, Benway T et al. Pharmacokinetics of N,N-dimethyltryptamine in Humans. Eur J Drug Metab Pharmacokinet 2023; 48 (3): 311-27.
  25. Griffiths RR, Johnson MW, Richards WA et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 2018; 32: 49-69.
  26. Gumpper RH, Roth BL. Psychedelics: preclinical insights provide directions for future research. Neuropsychopharmacology 2023; DOI: 10.1038/s41386-023-01567-7
  27. Inserra A. Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process. Front Pharmacol 2018; 9: 330.
  28. James E, Keppler J, Robertshaw TL et al. N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine. Human Psychopharmacology: Clinical and Experimental 2022; 37: e2835.
  29. Jiménez JH, Bouso JC. Significance of mammalian N,N-dimethyltryptamine (DMT): A 60-year-old debate. J Psychopharmacol 2022; 36: 905-19.
  30. Kagan S. The content of complex psychedelic experiences resulting from inhalation of N,N-dimethyltryptamine. J Psychedelic Stud 2023; 6: 222-31
  31. Kaplan J, Mandel LR, Stillman R et al. Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects. Psychopharmacologia 1974; 38: 239-45.
  32. Kargbo RB. Application of Deuterated N, N-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders. ACS Med Chem Lett 2022; 13: 1402-4.
  33. Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature 2009; 462: 175-81.
  34. Kelley DP, Venable K, Destouni A et al. Pharmahuasca and DMT Rescue ROS Production and Differentially Expressed Genes Observed after Predator and Psychosocial Stress: Relevance to Human PTSD. ACS Chem Neurosci 2022; 13: 257-74.
  35. Kozlowska U, Nichols C, Wiatr K et al. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. J Neurochem 2022; 162: 89-108.
  36. Luan L, Eckernäs E, Ashton M et al. Psychological and physiological effects of extended DMT. Journal of Psychopharmacology 2023; DOI: 02698811231196877.
  37. Ly C, Greb AC, Cameron LP et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep 2018; 23: 3170-82.
  38. Mohapatra SR, Sadik A, Sharma S et al. Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production. Front Immunol 2021; 12: 590532.
  39. Morales-García JA, De La Fuente Revenga M, Alonso-Gil S et al. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep 2017; 7: 5309.
  40. Morales-García JA, Calleja-Conde J, Lopez-Moreno JA et al. N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry 2020; 10: 331.
  41. Nemes B, Pető K, Németh N et al. N,N-dimethyltryptamine prevents renal ischemia-reperfusion injury in a rat model. In: Transplant Proc 2019; 51 (4): 1268-75.
  42. Olson DE. Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry 2022; 61 (3): 127-36.
  43. Olson DE. Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. J Exp Neurosci 2018; 12: 1179069518800508.
  44. Owen L, Sunram-Lea SI. Metabolic Agents that Enhance ATP can Improve Cognitive Functioning: A Review of the Evidence for Glucose, Oxygen, Pyruvate, Creatine, and l-Carnitine. Nutrients 2011; 3: 735-55.
  45. Peto K, Nemeth N, Mester A et al. Hemorheological and metabolic consequences of renal ischemia-reperfusion and their modulation by N,N-dimethyl-tryptamine on a rat model. Clinical Hemorheology and Microcirculation 2018; 70: 107-17.
  46. Ray TS. Psychedelics and the human receptorome. PLoS One 2010; 5: e9019.
  47. Riba J, Romero S, Grasa E et al. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology 2006; 186: 93-8.
  48. Ruffell SGD, Netzband N, Tsang W et al. Ceremonial Ayahuasca in Amazonian Retreats – Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study. Front Psychiatry 2021; 12: 687615.
  49. Saeger HN, Olson DE. Psychedelic‐inspired approaches for treating neurodegenerative disorders. J Neurochem 2021; 162 (1), 109-27.
  50. Sampedro F, de la Fuente Revenga M, Valle M et al. Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. International Journal of Neuropsychopharmacology 2017; 20: 698-711.
  51. Santos GHDM, Rodrigues LS, Rocha JM et al. Neural Network Modulation of Ayahuasca: A Systematic Review of Human Studies. Psychoactives 2023; 2: 76-91.
  52. Scott G, Carhart-Harris RL. Psychedelics as a treatment for disorders of consciousness. Neurosci Conscious 2019; 2019 (1): niz003; DOI: 10.1093/nc/niz003.
  53. Siegel JS, Nicol GE. Plasticity markers in the human brain associated with rapid antidepressants. Neuropsychopharmacology 2023; 48: 223-4.
  54. Strassman RJ, Qualls CR, Berg LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biological psychiatry 1996; 39: 784-95.
  55. Su T-P, Hayashi T, Vaupel DB. When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor. Sci Signal 2009; 2 (61): pe12; DOI: 10.1126/scisignal.261pe12.
  56. Szabo A. Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities. Front Immunol 2015; 6: 358.
  57. Szabo A, Kovacs A, Riba J et al., The endogenous hallucinogen and trace amine N, N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells. Frontiers in neuroscience 2016; 10: 423.
  58. Szabó Í, Varga VÉ, Dvorácskó S et al. N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain. Neuropharmacology 2021; 192: 108612.
  59. Timmermann C, Roseman L, Haridas S et al. Human brain effects of DMT assessed via EEG-fMRI. Proc Natl Acad Sci 2023; 120: e2218949120.
  60. Timmermann C, Roseman L, Schartner M et al. Neural correlates of the DMT experience assessed with multivariate EEG. Sci Rep 2019; 9: 16324.
  61. Timmermann C, Roseman L, Williams L et al. DMT Models the Near-Death Experience. Front Psychol 2018; 9: 1424.
  62. Turetzky RL. A Hermeneutic Phenomenology of the N,N-Dimethyltryptamine (DMT) Experience. Carpinteria 2022.
  63. Vargas MV, Dunlap LE, Dong C et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 2023; 379: 700-06.
  64. Vollenweider F. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. Neuropsychopharmacology 1997; 16: 357-72.
  65. Vogt SB, Ley L, Erne L et al. Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl Psychiatry 2023; 13: 172.
  66. Więckiewicz G, Stokłosa I, Piegza M et al. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals 2021; 14: 793.
  67. Yritia M, Riba J, Ortuno J et al. Determination of N,N-dimethyltryptamine and β-carboline alkaloids in human plasma following oral administration of ayahuasca. Journal of Chromatography B 2002; 779: 271-81.
  68. Zhang J, Qian H, Zhao P et al. Rapid Hypoxia Preconditioning Protects Cortical Neurons From Glutamate Toxicity Through δ-Opioid Receptor. Stroke 2006; 37: 1094-9.
ZGŁASZANIE PRAC
Udostępnij
without publication fees
without publication fees
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications